Professional
Added to YB: 2024-09-05
Pitch date: 2024-07-11
INSM [bullish]
Insmed Incorporated
+155.86%
current return
Author Info
No bio for this author
Upgrade to Yellowbrick Premium to unlock investor returns. Upgrade to Yellowbrick Premium
Company Info
Insmed Incorporated develops and commercializes therapies for patients with serious and rare diseases in the United States, Europe, Japan, and internationally.
Market Cap
$41.2B
Pitch Price
$77.00
Price Target
N/A
Dividend
N/A
EV/EBITDA
-42.82
P/E
-31.07
EV/Sales
90.08
Sector
Biotechnology
Category
growth
Show full summary:
Columbia Acorn Fund Portfolio Holding: Insmed Incorporated
INSM: Positive Phase III data for Brensocatib in NCFB treatment. No other approved therapies, multi-billion-dollar market potential. Stock doubled YTD but maintaining overweight position due to game-changing potential for pulmonary disease-focused biopharma.
Read full article (1 min)